Advanced search
Publication Cover
OncoTargets and Therapy Volume 12, 2019 - Issue
Submit an article Journal homepage
40
Views
3
CrossRef citations to date
0
Altmetric
Original Research

GADD45α-targeted suicide gene therapy driven by synthetic CArG promoter E9NS sensitizes NSCLC cells to cisplatin, resveratrol, and radiation regardless of p53 status

Qiwen Shi1 Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, Zhejiang, People’s Republic of China
,
Vijaykumar Sutariya2 College of Pharmacy, University of South Florida, Tampa, FL, USA
,
Sheeba Varghese Gupta2 College of Pharmacy, University of South Florida, Tampa, FL, USA
&
Deepak Bhatia3 Bernard J. Dunn School of Pharmacy, Shenandoah University, Ashburn, VA, USACorrespondence[email protected]
Pages 3161-3170 | Published online: 26 Apr 2019

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.